Why are tumour blood vessels abnormal and why is it important to know?
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Tumour blood vessels differ from their normal counterparts for reasons that have received little attention. We report here that they are of at least six distinct types, we describe how each forms, and, looking forward, encourage the targeting of tumour vessel subsets that have lost their vascular endothelial growth factor-A (VEGF-A) dependency and so are likely unresponsive to anti-VEGF-A therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although many in vitro microvessel models have been developed, none of them can actually reproduce the architecture of capillaries seen in a tumor [217,218].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [217]
Experimental — accuracy not yet measuredIn the citing paper
“The vasculature of tumors is very different from the blood vessels that supply healthy tissues, especially in terms of heterogeneity, permeability, multidirectional blood flow, and unordered distribution throughout the tumor160.”
From Tumor-on-a-chip: from bioinspired design to biomedical application (2021) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 1×
“Furthermore, recent successes with agents that block VEGF-A or its receptors have supported Folkman’s (1971) thesis that anti-angiogenesis can be a useful supplement to traditional tumour therapy.”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“As was noted more than 20 years ago, tumour angiogenesis shares many analogies with wound healing (Dvorak, 1986).”
BackgroundSelf-citationTransplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis
Hellström, M., Phng, L.-K., Hofmann, J. J., Wallgard, E., Coultas, L., Lindblom, P., Alva, J., Nilsson, A.-K., Karlsson, L., Gaiano, N., et al. (2007) · Nature · doi:10.1038/nature05571 · Cited by 1,775 · cited 1×
“…of endothelial cells: non-dividing ‘tip’ cells at the leading edge that extend filopodia and sprouts in response to VEGF-A gradients and ‘stalk’ cells that follow behind, divide and exhibit reduced filopodia and sprouting because of signalling through the Notch/delta 4 axis (Hellstrom et al, 2007).”
BackgroundBergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370 · cited 1×
“…that anti-VEGF/VEGFR approaches have effectively treated mouse tumours at early stages of their development, but have proved to be less successful in treating established mouse tumours that contain large numbers of more mature, smooth muscle-cell-coated blood vessels (Bergers et al, 2003).”
BackgroundBergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039 · cited 2×
“Agents that neutralise VEGF (e.g., Avastin, VEGF-TRAP) or its receptors have provided proof of principle that anti-angiogenesis can be a useful adjunct to tumour therapy (Jain et al, 2006).”
BackgroundRuhrberg, C., Gerhardt, H., Golding, M., Watson, R., Ioannidou, S., Fujisawa, H., Betsholtz, C., & Shima, D. T. (2002) · Genes & Development · doi:10.1101/gad.242002 · Cited by 914 · cited 2×
“Mice engineered to express only VEGF-A120 develop to term but generate a capillary network with larger-sized vessels and fewer branch points (Ruhrberg et al, 2002).”
BackgroundLee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D., & Iruela-Arispe, M. L. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200409115 · Cited by 703 · cited 2×
“Similar large, MV-like vessels can be generated by still smaller VEGF-As that result from matrix metalloprotease cleavage (Lee et al, 2005).”
BackgroundVasculogenic Mimicry and Tumor Angiogenesis
Folberg, R., Hendrix, M. J. C., & Maniotis, A. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64739-6 · Cited by 684 · cited 1×
“…and DV result, respectively, from arteriogenesis and venogenesis. aIn addition, red blood-cell-filled spaces lined by tumour cells rather than by vascular endothelium have been described in some tumours, particularly ocular melanomas, and are referred to as ‘vascular mimicry’ (Folberg et al, 2000).”
Background
Cited by
Items 301–400 of 612
Liu, L., Zhang, Y., Liu, H., Yang, J., Tian, Q., Chueakula, N., Ramasamy, S. K., Verma, N. K., Cheung, C., & Kusumbe, A. P. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4744 · Cited by 18
“However, the new rapidly formed blood vessels are immature and excessively branched, leading to their abnormal organization and heterogenicity, exhibiting notable structural and functional abnormalities, including increased vascular permeability (129).”
The Tumor Microenvironment Reprograms Immune Cells
Cao, H., Gao, S., Jogani, R., & Sugimura, R. (2022) · Cellular Reprogramming · doi:10.1089/cell.2022.0047 · Cited by 19
Dasgupta, A., Sawant, M. A., Lavhale, M. S., Krishnapati, L. S., Ghaskadbi, S., & Sitasawad, S. L. (2015) · Angiogenesis · doi:10.1007/s10456-015-9466-5 · Cited by 16
“Tumor angiogenesis causes excessive and aberrant microvessel branching as well as growth [8].”
BackgroundJamieson, L. E., Harrison, D. J., & Campbell, C. J. (2018) · Journal of Biophotonics · doi:10.1002/jbio.201800201 · Cited by 16
A four‐compartment multiscale model of fluid and drug distribution in vascular tumours
Shipley, R. J., Sweeney, P. W., Chapman, S. J., & Roose, T. (2020) · International Journal for Numerical Methods in Biomedical Engineering · doi:10.1002/cnm.3315 · Cited by 17
“The chamber-scale model (10) to (12) assumes that fluid flow on the length scale of the chamber is dominated by the arterioles and venules, followed by the capillaries and interstitium in turn (the fluid velocities in the arterioles and SHIPLEY ET AL.”
BackgroundMethodWang, Y., Li, G., Deng, M., Liu, X., Huang, W., Zhang, Y., Liu, M., & Chen, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107783 · Cited by 16
Vascular microphysiological systems (MPS): biologically relevant and potent models
Breuil, L., Kitada, A., Yadav, S., Zhou, H., Fujimoto, K., & Yokokawa, R. (2025) · Lab on a Chip · doi:10.1039/d5lc00014a · Cited by 19
Huang, K., Fu, P., Zhu, H., Feng, J., Zhang, L., Wang, B., Lu, Y., Zhang, D., Yao, M., Chen, L., et al. (2025) · Science Advances · doi:10.1126/sciadv.adz2046 · Cited by 15
Jiang, C., Feng, Q., Mao, Y., Zhang, Z., Xu, Y., Chen, Y., Zheng, P., Lin, S., Shen, F., Zhang, Z., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111771 · Cited by 14
Advancement of organ-on-chip towards next generation medical technology
Singh, G., Mishra, A., Mathur, A. K., Shastri, S., Nizam, A., Rizwan, A., Dadial, A. S., Firdous, A., & Hassan, H. (2024) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2024.100480 · Cited by 22
Bevacizumab-Based Therapies in Malignant Tumors—Real-World Data on Effectiveness, Safety, and Cost
Chitoran, E., Rotaru, V., Ionescu, S. O., Gelal, A., Capsa, C. M., Bohîlțea, R. E., Mitroiu, M.-N., Şerban, D., Gullo, G., Stefan, D.-C., et al. (2024) · Cancers · doi:10.3390/cancers16142590 · Cited by 21
“Moreover, the success of targeting the heterogeneous population of vessels in the tumor stroma is strongly influenced by the dependency of the VEGF effect on the state of cellular maturation, pericyte density, and the tumor stromal microenvironment [24–26].”
BackgroundLoon, N. W., Gendeh, B. S., Zakaria, R., Hamzah, J. C., & Din, N. M. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0490-7 · Cited by 15
“Abnormal blood supply via branches of the internal carotid artery especially for midline tumours has also been reported and this possibility cannot be ruled out [10, 11].”
BackgroundThe Biophysics of Cancer: Emerging Insights from Micro‐ and Nanoscale Tools
Beshay, P. E., Cortes-Medina, M. G., Menyhert, M. M., & Song, J. W. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100056 · Cited by 17
Koo, D.-J., Choi, J., Ahn, M., Ahn, B. H., Min, D., & Kim, S. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00263 · Cited by 16
Biochemical signals from the extracellular matrix in inflammation and tumour immunology
Sorokin, L. M. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-025-01248-0 · Cited by 18
Melanoma tumour vasculature heterogeneity: from mice models to human
Pautu, V., Mellinger, A., Resnier, P., Lepeltier, É., Martin, L., Boussemart, L., Letournel, F., Passirani, C., & Clere, N. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2809-z · Cited by 16
Nanospermidine in Combination with Nanofenretinide Induces Cell Death in Neuroblastoma Cell Lines
Lodeserto, P., Rossi, M., Blasi, P., Farruggia, G., & Orienti, I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061215 · Cited by 15
Gustafsson, J., Roshanzamir, F., Hagnestål, A., Patel, S. M., Daudu, O. I., Becker, D., Robinson, J. L., & Nielsen, J. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100583 · Cited by 16
Buck, J., Larkin, J. R., Simard, M. A., Khrapitchev, A. A., Chappell, M. A., & Sibson, N. R. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/4580919 · Cited by 14
Zadeh, E. S., Westhoff, C. C., Keber, C. U., Trenker, C., Dietrich, C. F., Alhyari, A., Mohr, C. G. L., & Görg, C. (2021) · Diagnostics · doi:10.3390/diagnostics11091601 · Cited by 14
“Furthermore, the chronic processes may reveal a rapid DE due to the abnormal veins and arteriovenous shunts associated with neoangiogenesis [17,29,34].”
BackgroundBenyahia, Z., Gaudy‐Marqueste, C., Berenguer‐Daizé, C., Chabane, N., Dussault, N., Cayol, M., Vellutini, C., Djemli, A., Nanni, I., Beaufils, N., et al. (2022) · Cancers · doi:10.3390/cancers14235909 · Cited by 13
Recent advances in micro-physiological systems for investigating tumor metastasis and organotropism
Yoon, H., del Río, J. S., Cho, S. W., & Park, T. (2024) · Lab on a Chip · doi:10.1039/d3lc01033c · Cited by 13
Exploring the potential of Toxoplasma gondii in drug development and as a delivery system
Yoon, C., Ham, Y. S., Gil, W. J., & Yang, C. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01165-7 · Cited by 19
Li, T., Wang, S., Zhao, Y., Wang, A., Zhang, L., Ruan, J., Fan, F., Liu, Y., Li, Y., Yue, Z., et al. (2016) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-015-2405-x · Cited by 13
Molecular approaches to equine sarcoids
Semik‐Gurgul, E. (2020) · Equine Veterinary Journal · doi:10.1111/evj.13322 · Cited by 14
Steinberger, K. J., Forget, M. A., Bobko, A. A., Mihalik, N. E., Gencheva, M., Roda, J. M., Cole, S. L., Mo, X. M., Hoblitzell, E. H., Evans, R., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000185 · Cited by 16
“However, the field has recognized that these vessels are thin-walled, leaky, tortuous and as a result, less efficient in delivering blood (34).”
BackgroundInfluentialCustom-made flow phantoms for quantitative ultrasound microvessel imaging
Adusei, S. A., Ternifi, R., Fatemi, M., & Alizad, A. (2023) · Ultrasonics · doi:10.1016/j.ultras.2023.107092 · Cited by 13
Lee, J. A., Biel, N. M., Kozikowski, R. T., Siemann, D. W., & Sorg, B. S. (2014) · Biomedical Optics Express · doi:10.1364/boe.5.001965 · Cited by 13
No patient left behind: The promise of immune priming with epigenetic agents
Carter, C. A., Oronsky, B. T., Roswarski, J., Oronsky, A. L., Oronsky, N. C., Scicinski, J. J., Lybeck, H., Kim, M. M., Lybeck, M., & Reid, T. R. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1315486 · Cited by 16
Alilou, M., Bera, K., Vaidya, P., Zagouras, A. A., Patil, P. D., Khorrami, M., Fu, P., Velcheti, V., & Madabhushi, A. (2019) · SPIE Medical Imaging: Computer-Aided Diagnosis · doi:10.1117/12.2513648 · Cited by 12
Bandt, S. K., de Rochefort, L., Chen, W., Dimov, A., Spincemaille, P., Kopell, B. H., Gupta, A. K., & Wang, Y. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.08.213 · Cited by 16
Flow‐Induced Vascular Remodeling on‐Chip: Implications for Anti‐VEGF Therapy
Mirzapourshafiyi, F., Huber, E., Karr, L., Tong, J., Bausch, A. R., Simmel, F. C., & Alim, K. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202501416 · Cited by 16
“These abnormalities are driven by the excessive release of VEGFs by tumor cells, associated with defective vascular maturation and remodeling [1], [2], [18].”
Multifarious targets beyond microtubules—role of eribulin in cancer therapy
Seshadri, P., Deb, B., & Kumar, P. (2021) · Frontiers in Bioscience-Scholar · doi:10.52586/s559 · Cited by 12
“In tumors, vascular networks are altered with complex branched patterns leading to decreased blood flow [53].”
BackgroundDeshmukh, K., Gupta, S., Mitra, K., & Bit, A. (2022) · Micromachines · doi:10.3390/mi13101766 · Cited by 13
Plessis, D., Gouws, C., & Nieto, D. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1391259 · Cited by 13
Neuber, C., Belter, B., Meister, S., Hofheinz, F., Bergmann, R., Pietzsch, H., & Pietzsch, J. (2018) · Molecules · doi:10.3390/molecules23020444 · Cited by 12
“In general, tumor blood and lymph vasculature is not only abnormal in almost all aspects of their structure, but also in their function [20–23].”
Blood Coagulation Factor Fibrinogen in Tumor Pathogenesis of Central Nervous System B-Cell Lymphoma
Chan, J. P., Merlini, M., Gao, H.-X., Mendiola, A. S., Akassoglou, K., Rubenstein, J. L., & Ryu, J. K. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.12.010 · Cited by 12
Sievert, M., Eckstein, M., Mantsopoulos, K., Mueller, S. K., Stelzle, F., Aubreville, M., Oetter, N., Maier, A., Iro, H., & Goncalves, M. (2021) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-021-06954-8 · Cited by 12
Blood vessel normalization in the hamster oral cancer model for experimental cancer therapy studies.
Molinari, A. J., Aromando, R. F., Itoiz, M. E., Garabalino, M. A., Hughes, A. M., Heber, E. M., Pozzi, E. C. C., Nigg, D. W., Trivillin, V. A., & Schwint, A. E. (2012) · PubMed · Cited by 12
Alexander, E. S., Xiong, L., Baird, G. L., Fernando, H. C., & Dupuy, D. E. (2020) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2019.09.010 · Cited by 12
Conventional Nanosized Drug Delivery Systems for Cancer Applications
Vergallo, C., Hafeez, M. N., Iannotta, D., Santos, H. A., d’Avanzo, N., Dini, L., Cilurzo, F., Fresta, M., Marzio, L. D., & Christian, C. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_1 · Cited by 15
Liu, Z., Wang, L. S., Yu, J., Zhang, J., Martel, E., & Li, S. (2025) · Bioengineering · doi:10.3390/bioengineering12101097 · Cited by 52
Lee, E. J., & Chang, Y.-W. (2024) · European Journal of Radiology · doi:10.1016/j.ejrad.2024.111432 · Cited by 11
Heating Induced Nanoparticle Migration and Enhanced Delivery in Tumor Treatment Using Nanotechnology
Gu, Q., & Zhu, L. K. (2024) · Bioengineering · doi:10.3390/bioengineering11090900 · Cited by 12
“It is well known that tumor blood vasculature forms rapidly to result in abnormal branching patterns and lumen structures [102].”
BackgroundSrinivas, B., Dasari, G., Syeda, A. B., Palabindela, R., & Srinivas, B. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102331 · Cited by 11
Cristini, N., Tavakoli, M., Sanati, M., & Yavari, S. A. (2025) · Journal of bone oncology · doi:10.1016/j.jbo.2025.100698 · Cited by 13
“These newly formed vessels are typically hyperpermeable and lack a fully developed basement membrane [66,67].”
Sabeti, S., Ternifi, R., Larson, N. B., Olson, M. C., Atwell, T. D., Fatemi, M., & Alizad, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1121664 · Cited by 13
“This leads to an abnormal tumor microenvironment characterized by low oxygen tension (51, 52).”
BackgroundFeng, S., & Yin, J. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-22-1073 · Cited by 18
“Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can provide high-resolution tumor anatomical information and functional information related to angiogenesis and blood flow status (10-12).”
The Dynamics of Developmental and Tumor Angiogenesis—A Comparison
Jin, Y., & Jakobsson, L. (2012) · Cancers · doi:10.3390/cancers4020400 · Cited by 11
Mohanty, K., Papadopoulou, V., Newsome, I. G., Shelton, S. E., Dayton, P. A., & Muller, M. M. (2019) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ab1a44 · Cited by 11
Lukina, M. M., Sirotkina, M. A., Orlova, A., Dudenkova, V. V., Komarova, A. D., Plekhanov, A. A., Snopova, L. B., Вадимовна, З. Е., Papkovsky, D. B., Shcheslavskiy, V. I., et al. (2020) · IEEE Journal of Selected Topics in Quantum Electronics · doi:10.1109/jstqe.2020.3047518 · Cited by 12
“and clinical settings has demonstrated the potential utility of OCA for monitoring antitumor therapy directed against the vasculature [12], [20].”
BackgroundThe Role of the VEGF Signaling Pathway in Tumor Angiogenesis
Ferrara, N. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_3 · Cited by 14
Ma, Z., Shi, H., Yin, M., Zhang, K., Zhong, W., Liu, Y., Luo, L., Liang, H., & Zhao, Y. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202507665 · Cited by 10
Unlocking the intricacies: Exploring the complex interplay between platelets and ovarian cancer
Xie, Q., Zhou, J., He, C., Xu, Y., Tao, F., & Hu, M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104465 · Cited by 10
Paul, M. S., & Zachar, Z. (2012) · InTech eBooks · doi:10.5772/48582 · Cited by 11
Carmona‐Rodríguez, L., Martínez-Rey, D., Martín-González, P., Franch, M., Sorokin, L. M., Mira, E., & Mañes, S. (2022) · Cancers · doi:10.3390/cancers14051226 · Cited by 11
“A corollary to the model proposed above is that high levels of SOD3 might increase the infiltration of anti-tumor effector T cells into the TME by reducing LAMA5 expression in ECs; since high density of CD8+ T cells has been associated to better prognosis in some types of cancer, LAMA5 levels might thus influence tumo…”
BackgroundInfluentialCross-scale tracing of nanoparticles and tumors at the single-cell level using the whole-lung atlas
Cao, Z., Zhao, Y., Sun, H., Sun, X., Zhang, Y., Zhang, S., Wang, C., Xiong, T., Naeem, A., Zhang, J., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh7779 · Cited by 11
Cytokines Regulating Trophoblast Invasion
Fitzgerald, J. S., Abad, C., Álvarez, Á. M., Mehta, R. B., Chaiwangyen, W., Dubinsky, V., Silva, B. G., Gutiérrez, G., Hofmann, S., Hölters, S., et al. (2011) · Advances in Neuroimmune Biology · doi:10.3233/nib-2011-023 · Cited by 11
“In tumors, VEGF is known to significantly contribute to pathological angiogenesis, tortuosity of tumor vasculatures and vasculogenesis, which all together lead to accelerated growth rates of tumors, invasion and metastasis [413].”
BackgroundHow does oncogene transformation render tumor cells hypersensitive to nutrient deprivation?
Leprivier, G., & Sorensen, P. H. B. (2014) · BioEssays · doi:10.1002/bies.201400085 · Cited by 10
Pizzimenti, S. (2014) · Journal of Pediatric Oncology · doi:10.14205/2309-3021.2014.02.01.5 · Cited by 11
“This leads to the building of a new, abnormal architecture and poorly functional blood vessels [47, 48], that fail to become quiescent because they lost the adequate control of pro- and anti-angiogenic factors.”
BackgroundDevelopment of a globally optimised model of the cerebral arteries
Keelan, J., Chung, E. M. L., & Hague, J. P. (2019) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ab2479 · Cited by 10
An evidence-based approach to red blood cell transfusions in asymptomatically anaemic patients
Chan, A., & de Gara, C. (2015) · Annals of The Royal College of Surgeons of England · doi:10.1308/rcsann.2015.0047 · Cited by 12
“Larger tumours tend to have more abnormal blood vessels that can bleed.(31) Furthermore, increased numbers of circulating inflammatory factors such as tumour necrosis factor alpha have been shown to suppress haemoglobin production.”
BackgroundEndogenous AJAP1 associates with the cytoskeleton and attenuates angiogenesis in endothelial cells
Hötte, K., Smyrek, I., Starzinski‐Powitz, A., & Stelzer, E. H. K. (2017) · Biology Open · doi:10.1242/bio.022335 · Cited by 12
“During tumor angiogenesis, de novo blood vessel formation is initiated by the unbalanced secretion of vascular endothelial growth factor A (VEGFA) by tumors and involves many of the same processes as those involved in physiological angiogenesis (reviewed in Nagy et al., 2009).”
BackgroundSheldon, H., Zhang, W., Bridges, E., Ang, K. H., Lin, S., Masiero, M., Li, D., Handford, P. A., Whiteman, P., Fischer, R., et al. (2022) · Journal of Extracellular Biology · doi:10.1002/jex2.52 · Cited by 10
“However, tumour angiogenesis is poorly co-ordinated and the resulting vessels are tortuous and leaky (Nagy et al., 2009).”
BackgroundAdusei, S. A., Sabeti, S., Larson, N. B., Dalvin, L. A., Fatemi, M., & Alizad, A. (2024) · Cancers · doi:10.3390/cancers16020395 · Cited by 9
“Malignant transformation of an existing nevus is also accompanied by the formation of new, aberrant, and structurally abnormal vessels [8,9].”
BackgroundUltrasound Localization Microscopy for Cancer Imaging
Porte, C., Dencks, S., Kohlen, M., Magnuska, Z., Lisson, T., Rix, A., Stickeler, E., Schmitz, G., & Kiessling, F. M. (2024) · IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control · doi:10.1109/tuffc.2024.3508266 · Cited by 11
High-Intensity Focus Ultrasound Ablation in Prostate Cancer: A Systematic Review
Yang, C., Barbulescu, D.-V., Marian, L., Tung, M., Ou, Y., & Wu, C.-H. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14121163 · Cited by 9
“In the microenvironment, the vascular structures become abnormal, characterized by malformed and atypical endothelium [72].”
Avolio, E., Bassani, B., Campanile, M., Mohammed, K. A. K., Muti, P. C., Bruno, A., Spinetti, G., & Madeddu, P. R. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100033 · Cited by 9
Hyperbaric oxygen augments Doxil antitumor efficacy by reducing tumor-induced lactate
Li, S., Wang, X., Fan, Z., Deng, Q., Han, D., Zhang, S., Xu, Q., Tian, Y., Li, J., Xu, C., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114181 · Cited by 9
Mirus, M., Tokalov, S. V., Wolf, G., Heinold, J., Prochnow, V., & Abolmaali, N. (2017) · European Radiology Experimental · doi:10.1186/s41747-017-0014-5 · Cited by 10
“As mentioned before, better vascularisation induces faster tumour growth that may impede the balance between nutrient supply and nutrient demand which may trigger regional critical shortness in blood supply leading to increased necrosis [27, 28].”
BackgroundNiland, S., Komljenovic, D., Macas, J., Bracht, T., Bäuerle, T., Liebner, S., & Eble, J. A. (2018) · Oncotarget · doi:10.18632/oncotarget.25032 · Cited by 9
“ATV and VM vessels have been suggested to be promising targets for drug delivery and antitumor therapy [1, 2, 23], in particular as the lack of ECs in VM-featuring tumors may be partially responsible for their resistance to treatment with anti-angiogenic agents, e.”
BackgroundInfluentialFroelich, M. F., Petersen, E. L., Heinemann, V., Nörenberg, D., Hesse, N., Gesenhues, A. B., Modest, D. P., Sommer, W. H., Hofmann, F. O., Stintzing, S., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.06.005 · Cited by 9
Gandolfi, A., de Franciscis, S., d’Onofrio, A., Fasano, A., & Sinisgalli, C. (2020) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2020.110526 · Cited by 9
Torii, M., Fukui, T., Inoue, M., Kanao, S., Umetani, K., Shirai, M., Inagaki, T., Tsuchimochi, H., Pearson, J. T., & Toi, M. (2017) · Journal of Synchrotron Radiation · doi:10.1107/s1600577517008372 · Cited by 9
“Tumor vessels have highly irregular networks, ISSN 1600-5775 immature vessel structures and abnormal blood flow as compared with normal vessels of normal tissues (Jain, 1988; Fukumura & Jain, 2008; Nagy et al., 2009).”
BackgroundHu, F., Martin, H., Martinez, A. F., Everitt, J. I., Erkanli, A., Lee, W. T., Dewhirst, M. W., & Ramanujam, N. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1058 · Cited by 11
“Overexpression of VEGF has been observed in DMBAtreated hamster oral mucosa (26,27) as a marker of angiogenesis (28,29), suggesting that the changes we observed here are due in part to increasing VEGF over the course of neoplastic progression.”
BackgroundMiller, J. P., Wang, S. T., Orukari, I. E., Prior, J. L., Sudlow, G. P., Su, X., Liang, K., Tang, R., Hillman, E. M. C., Weilbaecher, K. N., et al. (2017) · Journal of Biophotonics · doi:10.1002/jbio.201700232 · Cited by 9
Leszczyński, B., Śniegocka, M., Wróbel, A., Pedrys, R., Szczygieł, M., Romanowska‐Dixon, B., Urbańska, K., & Elas, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020332 · Cited by 9
“The blood flow in the vessels in a tumor is a very important parameter, because it helps determine the tumor microenvironment and tumor response to different therapeutic approaches and is inseparably connected with chemotherapeutic-agent delivery [32].”
Ion Transport and Radioresistance
Roth, B., & Huber, S. M. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_33 · Cited by 10
Development of a globally optimised model of the cerebral arteries
Keelan, J., Chung, E. M. L., & Hague, J. P. (2019) · Open Research Online - ORO (The Open University) · Cited by 9
Minajeva, A., Kase, M., Saretok, M., Adamson-Raieste, A., Kase, S., Niinepuu, K., Vardja, M., Asser, T., & Jaal, J. (2017) · Neuroscience Journal · doi:10.1155/2017/5629563 · Cited by 10
“In addition to their distinct morphology, it is widely known that angiogenic blood vessels in tumors have abnormal function accompanied by high levels of local VEGF-A expression and increased expression of intercellular adhesion molecule-1 (ICAM-1) as well as permeability [19].”
BackgroundNanoimmunotherapy – cloaked defenders to breach the cancer fortress
Kandasamy, G., Annenkov, V. V., & Krishnan, U. M. (2018) · Nanotechnology Reviews · doi:10.1515/ntrev-2018-0013 · Cited by 10
“Hence, anti-VEGF therapies are directed against this molecule or its receptors [23].”
BackgroundTumor Vasculature, EPR Effect, and Anticancer Nanomedicine: Connecting the Dots
Taurin, S., Nehoff, H. L., van Aswegen, T., & Greish, K. F. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7876-8_8 · Cited by 10
“7 79 33 3 C D 34 [ 2 26 ]”
InfluentialIntermedin restricts vessel sprouting by inhibiting the loosening of endothelial junction
Xiao, F., Wang, L., Zhao, H., Chun, T., Wang, D., Zhang, H., Wei, Y., Liu, J., & Zhang, W. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.090 · Cited by 9
Gu, Q., Dockery, L. T., Daniel, M., Bieberich, C. J., Ma, R., & Zhu, L. K. (2021) · Fluids · doi:10.3390/fluids6080272 · Cited by 10
“Blood vessels within tumors lack fundamental structures and branching patterns when compared to those in healthy tissues [15].”
BackgroundSerum starvation-based method of ovarian cancer cell dormancy induction and termination in vitro
Rutecki, S., Leśniewska-Bocianowska, A., Chmielewska, K., Matuszewska, J., Naumowicz, E., Uruski, P., Radziemski, A., Mikuła‐Pietrasik, J., Tykarski, A., & Książek, K. (2023) · Biology Methods and Protocols · doi:10.1093/biomethods/bpad029 · Cited by 10
“Finally, we employed serum starvation as the driver of EOC dormancy, based on the high nutrient demands of cancer cells that may not be satisfied in vivo due to inadequate blood flow through functionally and structurally malformed vessels [19].”
MethodCeci, C., García‐Chico, C., Atzori, M. G., Lacal, P. M., Lista, S., Santos‐Lozano, A., Graziani, G., & Pinto-Fraga, J. (2023) · Journal of Cancer · doi:10.7150/jca.88559 · Cited by 10
“The new vascular system, however, lacks a regular and hierarchical organization, exhibiting a chaotic and tortuous structure [52,53].”
BackgroundNovel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?
Bozza, C., Fontanella, C., Buoro, V., Mansutti, M., & Aprile, G. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1001837 · Cited by 8
“Besides, the disorganized vascularization makes some cancer areas chronically hypoxic and acidic [5], and this unfavorable condition further promote the expression of growth factors such as VEGF [6].”
BackgroundModulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors
Gupta, S., & Dwarakanath, B. S. R. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180601101145 · Cited by 8
Astrocytoma and glioblastoma IDH1-wildtype cells colonize tumor vessels and deploy vascular mimicry
Maraqah, H. H., Abu-Asab, M. S., Lee, H. S., & Aboud, O. (2023) · Ultrastructural Pathology · doi:10.1080/01913123.2023.2205927 · Cited by 8
Excess centrosomes induce p53‐dependent senescence without DNA damage in endothelial cells
Yu, Z., Ruter, D. L., Kushner, E. J., & Bautch, V. L. (2017) · The FASEB Journal · doi:10.1096/fj.201601320r · Cited by 9
Isolation of tumor endothelial cells from murine cancer
Taguchi, K., Onoe, T., Yoshida, T., Yamashita, Y., Taniyama, K., & Ohdan, H. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.11.005 · Cited by 9
“It has been indicated that the morphology and gene expression of TECs differ from those of normal endothelial cells (St Croix et al., 2000; Jain, 2003; Lu et al., 2007; Nagy et al., 2009; Hida et al., 2011; Hida et al., 2013).”
BackgroundKallio, P., Jokinen, E., Högström, J., Das, S., Heino, S., Lähde, M., Brodkin, J., Korhonen, E. A., & Alitalo, K. K. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0497 · Cited by 8
Yu, J., Mu, Q., Perazzolo, S., Griffin, J. I., Zhu, L., McConnachie, L. A., Shen, D. D., & Ho, R. J. Y. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02888-8 · Cited by 8
Kontrastverstärkte Sonographie in der Lymphknotendiagnostik
Weskott, H. (2018) · Der Radiologe · doi:10.1007/s00117-018-0389-1 · Cited by 8
Bodard, S., Denis, L., Chabouh, G., Anglicheau, D., Hélénon, O., Corréas, J.-M., & Couture, O. (2024) · Theranostics · doi:10.7150/thno.100897 · Cited by 7
Advances in extracellular Vesicle-based cancer precision medicine
Ilamathi, H. S., Rinaldo, G., & Wiklander, O. P. B. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217976 · Cited by 8
An imaging-based stochastic model for simulation of tumour vasculature
Adhikarla, V., & Jeraj, R. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/19/6103 · Cited by 8
The E3 ubiquitin-protein ligase MDM2 is a novel interactor of the von Hippel–Lindau tumor suppressor
Falconieri, A., Minervini, G., Bortolotto, R., Piovesan, D., Lopreiato, R., Sartori, G., Pennuto, M., & Tosatto, S. C. E. (2020) · Scientific Reports · doi:10.1038/s41598-020-72683-3 · Cited by 7
Vascular phenotyping of the invasive front in breast cancer using a 3D angiogenesis atlas
Bhargava, A., Popel, A. S., & Pathak, A. P. (2023) · Microvascular Research · doi:10.1016/j.mvr.2023.104555 · Cited by 10
Wang, S., Wang, T., Guo, S., Zhu, S., Chen, R., Zheng, J., Jiang, T., Li, R., Li, J., Li, J., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02871-9 · Cited by 7
Metadata
- Authors
- Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Dvorak, H F
- ORCID
- Nagy, J A
- Venue
- British Journal of Cancer
- Published
- 2009-02-24
- Volume
- 100
- Issue
- 6
- Pages
- 865-869
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2661770
- OpenAlex
- W2063556542
- Cited by
- 611
- References
- 38
- Citations by year
- 2026: 30 · 2025: 39 · 2024: 62 · 2023: 47 · 2022: 50 · 2021: 53 · 2020: 61 · 2019: 47 · 2018: 51 · 2017: 48 · 2016: 22 · 2015: 16 · 2014: 12 · 2013: 18 · 2012: 20
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- National Heart, Lung, and Blood Institute (R01HL064402, HL-64402)
- National Cancer Institute (P01 CA 92644, P01CA092644)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor vasculature, VEGF-A, anti-VEGF therapy, tumor angiogenesis, anti-angiogenic therapy resistance
- MeSH terms
- Animals, Blood Vessels, Capillaries, Humans, Neoplasms, Neovascularization, Pathologic, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.